Evidence map›Paper›PMID 29417184›Full record

ArticleDiabetologia2018

Galectin-3 is independently associated with progression of nephropathy in type 2 diabetes mellitus.

Kathryn C B Tan, Ching-Lung Cheung, Alan C H Lee, Joanne K Y Lam, Ying Wong, Sammy W M Shiu

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Diabetologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Cardiac Biomarkers in Chronic Kidney Disease: Signal or Noise?Clinical journal of the American Society of Nephrology : CJASN · 2026
    Review
  7. Article
  8. Article
  9. Pleiotropic regulatory mechanisms and targeted therapeutic prospects of Galectin-3 in aging-related diseases.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Galectin-3: action and clinical utility in chronic kidney disease.International urology and nephrology · 2024
    Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Kathryn C B TanDepartment of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong Special Administrative Region, People's Republic of China. kcbtan@hku.hk.
Ching-Lung CheungDepartment of Pharmacology and Pharmacy, University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.
Alan C H LeeDepartment of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong Special Administrative Region, People's Republic of China.
Joanne K Y LamDepartment of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong Special Administrative Region, People's Republic of China.
Ying WongDepartment of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong Special Administrative Region, People's Republic of China.
Sammy W M ShiuDepartment of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong Special Administrative Region, People's Republic of China.
University of Hong Kong · HKQueen Mary Hospital · CN

Funding

Endowment Fund established for the "Sir David Todd Professorship in Medicine" N/A
6 · The paper itself

Abstract

aims/hypothesisGalectin-3 has been implicated in cardiac and renal fibrosis and serves as a prognostic clinical indicator in heart failure. The aim of the present study was to evaluate whether serum galectin-3 level is associated with progressive kidney disease in type 2 diabetes.

methodsGalectin-3 was measured in baseline samples by ELISA in 1320 participants with type 2 diabetes with eGFR ≥30 ml min

resultsSerum galectin-3 levels were significantly increased in a random subgroup of 270 type 2 diabetic individuals with eGFR >60 ml min CONCLUSIONS/

interpretationSerum galectin-3 was independently associated with progressive renal disease in type 2 diabetes. Further mechanistic studies are warranted to determine whether galectin-3 is simply a disease biomarker or is also a mediator of the development and progression of diabetic nephropathy.

Indexed as

AlbuminuriaBiomarkersBlood ProteinsCreatinineDiabetes Mellitus, Type 2Diabetic NephropathiesDisease ProgressionFemaleFollow-Up StudiesGalectin 3GalectinsGlomerular Filtration RateHumansKidney Failure, ChronicMaleMiddle AgedBiomarkersBlood ProteinsCreatinineGalectin 3GalectinsLGALS3 protein, humanDiabetic nephropathyDoubling of creatinineGalectin-3Incident macroalbuminuriaRenal fibrosisType 2 diabetes

Identifiers

PMID29417184
OpenAlexW2789349492

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.